Ignite Creation Date:
2025-12-24 @ 9:34 PM
Ignite Modification Date:
2025-12-31 @ 10:21 PM
Study NCT ID:
NCT01273532
Status:
COMPLETED
Last Update Posted:
2012-03-13
First Post:
2011-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR017602
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Senior Director, Clinical Leader
Old Organization:
Johnson & Johnson Pharmaceutical Research and Development, L.L.C.